aGroup 1: “intermediate” patients, Group 2: younger patients with sever
e comorbidities, Group 3: elderly patients with few cardiovascular comorbidities, Group 4: patients who initiated cinacalcet; bResults are presented as mean ± SD; cBody massindex; pcorresponds to ANOVA.